47 results about "Sulfatase" patented technology

The invention discloses a sulfatase-driven polypeptide condensate with a chemotherapy sensitization effect and a preparation method thereof, and belongs to the field of biological medicines. According to the principle that sulfatase can catalyze hydrolysis of sulfate bonds, main polypeptide YSO4F responded by sulfatase enzyme is designed and synthesized; and the enzyme response aggregate m-YSO4F-LSG is blended with a protein G3BP2 ligand FGDF-YSO4F to prepare the enzyme response aggregate m-YSO4F-LSG with a sorafenib chemosensitization effect. Tumor cells can generate stress particles with a chemotherapy drug resistance effect under the stimulation of a chemotherapy drug sorafenib, the treatment effect of the sorafenib is weakened, and the protein G3BP2 is one of core proteins of the stress particles. After the m-YSO4F-LSG enters tumor cells, sulfate groups are hydrolyzed under the catalytic action of sulfatase overexpressed in tumor cell lysosomes, so that phase separation liquid drops d-YF-LSG with high affinity to protein G3BP2 are formed in the cells in situ, the phase separation liquid drops d-YF-LSG act with the protein G3BP2 and are fused with stress particles, chemotherapy drug resistance generated by the stress particles is inhibited, and the chemotherapy effect is improved. The treatment effect is improved.

An object of the present invention is to provide a lactase solution showing good permeation through a filtration filter, a lactase solution showing good permeation through a filtration filter and having a good residual lactase activity, and a lactase solution showing good permeation through a filtration filter and having a good residual lactase activity even when a lactase solution having a low protease activity and a low arylsulfatase activity as contaminant enzymes is used.A lactase solution containing any of (i) to (iii) below.(i) 0.0001 to 0.1 mass % of an unsaturated fatty acid or a salt thereof(ii) 0.0001 to 0.1 mass % of a saturated fatty acid salt(iii) 0.01 to 10 mass % of at least one selected from yeast extract, soybean peptone, pea protein, a casein degradation product, and corn steep liquor

To provide formulations of protein molecules comprising iduronate 2-sulfatase.SOLUTION: Certain embodiments provide a pharmaceutical composition comprising a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide, a buffer, an isotonicity agent, a surfactant, and a stabilizer, wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, and further provide methods of use thereof. In certain embodiments, the buffer is selected from the group consisting of phosphate buffer, acetate buffer, arginine buffer, and histidine buffer. In certain embodiments, the phosphate buffer is a sodium phosphate buffer or a potassium phosphate buffer.SELECTED DRAWING: None

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.

The present invention belongs to the field of biomedical technologies and discloses the use of arylsulfatase K in the preparation of drugs for preventing, delaying or treating chronic obstructive pulmonary disease. The present invention has for the first time discovered the role of ARSK (arylsulfatase K) in inhibiting mitophagy and delaying the senescence of airway epithelial cells, and further determined the key role of ARSK in the occurrence and development of COPD, which can provide a new target for the prevention and treatment of COPD. The present invention has determined that ARSK can slow down the process of lung senescence by alleviating the process of mitophagy, inhibiting the senescence of airway epithelial cells, thereby providing a new treatment strategy for COPD.

The invention provides compositions and methods for the treatment of lysosomal storage diseases such as metachromatic leukodystrophy and related disorders. A significant unmet clinical need still exists with the current clinical lentiviral vectors due to the high integration requirement and currently insufficient levels of ARSA expression to correct onset of early symptomatic disease. Methods and compositions for producing a protein such as sulfatase and for treating a disease or disorder such as metachromatic leukodystrophy and related disorders are disclosed.

Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.

The present invention relates to a pharmaceutical composition for CNS delivery of high-concentration heparan N-sulfatase (HNS) with improved stability, and a pharmaceutical dosage form containing the same. The pharmaceutical composition and pharmaceutical dosage form containing the same according to the present invention have excellent dosage form stability, such as reduced turbidity and significantly improved purity, and are therefore useful in enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis type III.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Phocaediola doleeri, and further discloses a use of the Phocaediola doleeri in preparing a product for preventing and treating glycolipid metabolic disorder. A YG0564 strain is screened from healthy adult feces, and is identified as the Phocaediola doleeri and classified and named as Phocaediola doleeri. The Phocaediola doleeri strain YG0564 contains cholesteryl sulfatase, and can significantly reduce blood fat and blood sugar in vivo and in vitro, and can obviously prevent and treat obesity and glycolipid metabolic disorder.

The present invention relates to a pharmaceutical composition for preventing or treating Sanfilippo syndrome type A (MPS IIIA) comprising heparan N-sulfatase (HNS), and more particularly, to an optimal dose and period of administration of heparan N-sulfatase, which can effectively reduce the accumulation of heparan sulfate (HS) while improving the cognition of patients. According to the present invention, it can be used as enzyme replacement therapy (ERT) for treating Sanfilippo syndrome type A.

The present invention provides, inter alia, methods of treating metachromatic white matter dystrophy disease (MLD) and compositions comprising a recombinant arylsulfatase A (ASA) protein using enzyme replacement therapy.

This invention provides a method for synthesizing the compound DDAO-Sulfate, belonging to the field of chemical synthesis technology. The method includes the following steps: mixing DDAO and sodium ethoxide with anhydrous dimethylformamide to obtain a mixed solution; adding pyridine sulfur trioxide to the mixed solution and heating and stirring the reaction under light-protected conditions; subsequently concentrating under vacuum to obtain a residue; and purifying the residue by column chromatography using an eluent to obtain the final product. This synthetic method effectively improves the yield while selecting and optimizing the reactants, avoiding the use of easily deteriorated reagents and interference caused by the introduction of irrelevant substances, thus providing an efficient pathway for the preparation of fluorescent detection probes for sulfatase.

The invention discloses a high-temperature-resistant instant carrageenan composition and a preparation method thereof. The carrageenan composition comprises the following components in percentage by mass: 20-30% of modified carrageenan, 5-15% of a functional aid, 0.1-0.5% of a crosslinking regulator, 1-5% of a solubilizing accelerant and the balance of deionized water. The invention belongs to the technical field of food additives and processing, equidistant substitution of hydroxyl groups is realized at the C6 site of carrageenan through a bacillus subtilis sourced sulfatase and flavin monooxygenase concerted catalysis system, the problem of large fluctuation of high-temperature dissolution rate caused by non-uniform distribution of functional groups in existing hydroxylation modification is remarkably improved, and the stability of the carrageenan is improved. The high temperature resistance of the carrageenan composition is improved; meanwhile, the dissolving property is enhanced.

The present invention pertains to a novel treatment of pathologies caused by an increased synthesis or accumulation of sulfolipids such as sulfatide. The invention provides mutated arylsulfatase A (ARSA or ASA, EC 3.1.6.8) enzymes with increased activity towards sulfatide metabolization. The invention provides nucleic acids encoding the mutant ARSA, the use of the proteins and nucleic acids, as well as pharmaceutical compositions comprising them, in the treatment of lysosomal storage disorders (LSDs) such as metachromatic leukodystrophy (MLD).

The present application relates to the technical field of drug residue detection, and in particular to a general pre-treatment method based on immunoaffinity rapid detection. A general pre-treatment method based on immunoaffinity rapid detection, comprising the following steps: using reagent 1, reagent 2, reagent 3, reagent 4, reagent 5 to process the sample to be tested in sequence, wherein the reagent 1 is ammonium citrate buffer; the reagent 2 is β-glucuronidase; the reagent 3 is arylsulfatase; the reagent 4 is a mixture of acetonitrile, methanol, ethanol and an organic acid; the organic acid is citric acid or formic acid; the reagent 5 is N-propylethylenediamine. The pre-treatment method of the present application is applicable to the pre-treatment of the residue detection of multiple major drugs involved in veterinary drug residues in current animal food, and solves the problem that food safety detection usually requires the determination of multiple drugs on the same sample, and multiple pre-treatment operations are required, and the time, equipment and reagent consumption are large.

The invention discloses a TE enzyme mutant with improved activity and application thereof, and belongs to the technical field of biology. Schrodinger molecular docking is combined with fixed-point saturation mutation to establish a mutant library, Rosetta is used for screening the mutant library, searching a target point and carrying out single-point mutation and combined mutation, the activity of thioesterase is improved, the synthesis efficiency of Surfactin is further improved, and a production strain with better fermentation performance in industrial production is obtained. Through verification, mutations comprise A113W, A113G, K122H, K192D and a combination of the A113W, the A113G, the K122H and the K192D, fermentation verification shows that the yield of the Surfactin is increased by 41.2% to the maximum compared with that of a wild type and reaches 9.6 g / L, thioesterase with higher activity and a production strain with better fermentation performance in industrial production are obtained, and powerful support is provided for efficient production of the Surfactin.

This disclosure relates to a liquid thiosynergist, to an antioxidant composition comprising the same, to a polymer composition comprising the antioxidant composition, to use of the antioxidant composition for stabilizing polymer, and to a process of synthesizing the liquid thiosynergist.

The present invention discloses a two-photon fluorescent probe and its application in sulfatase detection, wherein the structure of the endoplasmic reticulum-targeted two-photon fluorescent probe is shown below: #imgabs0#. The endoplasmic reticulum-targeted two-photon fluorescent probe of the present invention responds to different concentrations of sulfatase, with a detection limit as low as 0.12 U / L and a two-photon absorption cross section of 81 GM. Cytotoxicity tests demonstrate that the probe has low biological toxicity. Confocal fluorescence microscopy imaging demonstrates that the probe can effectively target the endoplasmic reticulum in HeLa cells (localization coefficient of 0.86), making it suitable for fluorescent imaging detection of sulfatase in the endoplasmic reticulum of living cells.

Provided herein are gene therapy methods for the treatment of mucopolysaccharidosis type IVA (MPS IVA) involving the use of recombinant lentivirus (LV) to deliver human N- acetylgalactosamine-6-sulfate sulfatase (hGALNS) to the bone of a human subject diagnosed with MPS IVA. Also provided herein are LV-hGALNS that can be used in Hematopoietic Stem Cell Gene Therapy (HSC-GT) methods.

The present invention relates to a high concentration heparan N-sulfatase (HNS) pharmaceutical composition with enhanced stability for CNS delivery and a pharmaceutical formulation comprising the same. The pharmaceutical composition and the pharmaceutical formulation comprising the same according to the present invention have excellent formulation stability, such as reduction of turbidity and significant improvement of purity, which can be used in enzyme replacement therapy (ERT) for the treatment of type III mucopolysaccharide storage disease.

The invention relates to the technical field of seaweed active component extraction, and discloses a gradient enzymolysis-ultrasonic coupling double-seaweed active component extraction process, which solves the problems proposed in the background technology, and comprises the following steps: 1, brown algae pretreatment and first-stage enzymolysis; the preparation method comprises the following steps: crushing a brown algae raw material until the particle size is 50-100 meshes, and adding a buffer solution with the pH value of 5.0-6.0 according to a material-liquid ratio of 1: 15-1: 20; adding cellulase, carrying out enzymolysis at 45-50 DEG C for 30-60 minutes, and synchronously applying 28kHz / 300W pulse ultrasound; adjusting the pH value of the system to 7.0-7.5, adding alginate lyase, and continuing enzymolysis at 50-55 DEG C for 40-80 minutes; 2, green algae pretreatment and second-stage enzymolysis; the preparation method comprises the following steps: crushing a green alga raw material until the particle size is 80-120 meshes, and adding a buffer solution with the pH value of 6.5-7.0 according to a material-liquid ratio of 1: 10-1: 15; adding xylanase and sulfatase, carrying out enzymolysis for 60-90 minutes at 55-60 DEG C, and synchronously applying 35kHz / 500W continuous ultrasonic waves. The method has the effects of increasing the extraction rate, reducing the energy consumption and being high in activity retention rate.

The present invention provides compositions used for the treatment and / or prevention of protein aggregation disorders. [Solution] Proteopathy encompasses a wide range of ailments, including neurodegenerative diseases (e.g., polyglutamine diseases such as huntingtin in Alzheimer's disease, Parkinson's disease, and Huntington's disease, and prion diseases); amyloidosis of other non-neuronal proteins (especially I1-antitrypsin, immunoglobulin light and heavy chains, lactadherin, apolipoprotein, gelzolin, lysozyme, fibrinogen, atrial natriuretic factor, keratin, lactoferrin, and β-2 microglobulin, etc.); sickle cell disease; cataracts; cystic fibrosis; retinitis pigmentosa; and nephrogenic diabetes insipidus. Administration of sulfatase inhibitors is generally suitable for treating and / or preventing protein toxicity associated with proteopathy. Therefore, the present invention provides compositions comprising sulfatase inhibitors for the treatment of proteopathy.

The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.

The present disclosure provides an anti-sulfatase-related antigen specific antibody, a detection kit including the anti-sulfatase-related antigen specific antibody, and a method for detecting osteoarthritis by using the anti-sulfatase-related antigen specific antibody. The present disclosure achieves the effect of detecting osteoarthritis through various efficacy experiments.

The application discloses a kind of biological enzyme deodorization antibacterial agent for sewage treatment, including: biological complex enzyme preparation 10~30 parts by weight, probiotic preparation 5~15 parts by weight, carrier 40~70 parts by weight, auxiliary agent 1~8 parts by weight;Biological complex enzyme preparation includes at least three kinds of protease, lipase, cellulase, urease and sulfatase;Probiotic preparation includes at least one of bacillus, lactic acid bacteria, photosynthetic bacteria;Preparation method includes: carrier drying, crushing and sieving, obtain pretreated carrier;Biological complex enzyme preparation, probiotic preparation and auxiliary agent are uniformly mixed to obtain mixed powder;Mixed powder and pretreated carrier are stirred and mixed under normal temperature sterile condition to obtain primary product;Primary product is dried and sieved at low temperature to obtain biological enzyme deodorization antibacterial agent.The application has the advantages that: solve the secondary pollution, short-term effect, poor synergy and complex preparation of existing deodorization antibacterial agent, realize efficient deodorization, long-acting antibacterial and no secondary pollution, and the preparation process is simple, cost controllable.

In the present disclosure, a yeast interactive plasmid of a detoxifying enzyme glucosinolate sulfatase (GSS1) is constructed based on a yeast two-hybrid system and then screened with an Arabidopsis thaliana-yeast library, and a plant protein zeaxanthin epoxidase aba1 that interacts with the GSS1 is obtained for the first time. A zeaxanthin epoxidase gene, also known as an aba-1 gene, is an abscisic acid (ABA) synthase that can catalyze oxidative conversion of the zeaxanthin into all-trans violaxanthin, thereby generating carotenoid precursors required in an ABA biosynthetic pathway. Furthermore, a core peptide segment that interacts with the aba1 is obtained by continuously reducing the length of a GSS1 sequence and conducting one-to-one yeast two-hybrid verification with the aba1 sequence.

The invention discloses a method for evaluating electronic waste pollution exposure risk based on a simple function, and the method comprises the following steps: collecting urine of crowds in an electronic waste pollution potential exposure area, centrifuging a urine sample, taking supernate, sequentially adding 1% formic acid, an internal standard solution and a beta-glucuronidase / aryl sulfatase mixed solution, and uniformly stirring; the method comprises the following steps of: performing enzymolysis, extracting and enriching, taking supernate, performing instrumental analysis to obtain the concentrations of 2, 4, 6-TriBP, 2, 4, 5-TriCP and 4-MonoBP in the urine, measuring the concentration of creatinine in the urine, and correcting; constructing three judgment functions, wherein the numbers of the three functions are all 1t; and when 0, judging that the crowd is exposed to the electronic waste. According to the method, geometric visualization and function explicit of decision logic are realized in a mode of combining feature importance analysis and decision boundary projection, and finally three simplified functions which are convenient for practical application and are used for predicting the exposure risk of electronic waste pollution are formed.

The present invention relates to a lyophilized preparation containing, as an active ingredient, a fusion protein of an antibody and heparan N-sulfatase (SGSH), the lyophilized preparation further comprising an isotonic agent, a nonionic surfactant, and a buffering agent, wherein the nonionic surfactant contains polysorbate and poloxamer, and the buffering agent contains histidine.

Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.